for NIH Molecular Libraries Program centers by assay submitter.
PubChem's data source information page can be found here.
Probe Reports (reported by Molecular Libraries website)
The Molecular Libraries Program website lists the publicly available Probe reports from all centers but has not been updated for a while. It can be found here. We keep our own up to date copy of Scripps' Center probes here.
Google Scholar Citations for PubMed
This tool will take a PubMed PMID and run a Google search to obtain the number of times it has been cited. The resulting Google Scholar link is inserted into the PubMed page as shown in the picture.
To use this tool you will need to be using the Firefox browser with the Greasemonkey extension installed. You can then install the tool here.
1,631 PubChem assays, 49,424,725 tested substances, 437,346 active substances, 72 probes and 141 publications, with 5435 citations
MS Drug Discovered at TSRI is Safe and Effective
in Phase II Study
A compound discovered
and synthesized in The Scripps Research Institute (TSRI) labs of
Professors Hugh Rosen and Edward Roberts has provided positive
results for safety and efficacy in Phase 2 clinical trials for
relapsing multiple sclerosis, according to Receptos, the
biopharmaceutical company developing the drug for approval by the
US Food and Drug Administration.
“The Rosen and Roberts
laboratories are very gratified to see these direct improvements in
the lives of patients and families dealing with this debilitating
illness,” said Rosen. “These data support our labs' approach at
TSRI—that discovery of fundamental mechanisms in chemical biology
provides the foundation for intelligent intervention in disease
processes. Meeting the needs of patients and their families is our
high calling in biomedical science.”
The drug candidate,
RPC1063, was first discovered at TSRI from work in the National
Institutes of Health (NIH) Molecular Libraries Initiative. The
randomized, double-blind Phase 2 study assessed the efficacy,
safety and tolerability of two orally administered doses of RPC1063
against placebo in 258 patients with relapsing multiple sclerosis
across 77 sites in 13 countries. There was a highly statistically
significant 86 percent reduction in MRI measures of disease
A Phase 3 trial—a
randomized, double-blind study involving 1,200 patients with
relapsing multiple sclerosis—was launched in December 2013.